---
title: 'Adderall Generic Name Explained: Complete Guide for Clinicians'
date: '2026-07-15'
slug: adderall-generic-name-explained-complete-guide-for-clinicians
description: Discover the official generic name of Adderall, its amphetamine salts,
  FDA labeling, and how clinicians can verify the formulation.
updated: '2026-07-15'
author: Dr. Benjamin Paul
site: Rounds AI
---

# Adderall Generic Name Explained: Complete Guide for Clinicians

## Why Knowing the Generic Name of Adderall Matters to Clinicians

Clinicians often conflate the brand name Adderall with its generic designation, mixed-amphetamine salts. That confusion increases the risk of prescribing, dispensing, and billing errors at the point of care. Using the precise generic name improves documentation, supports formulary checks, and clarifies prescribing intent. Across NHS primary care, generic prescribing can cut drug spend by up to [30%](https://www.sps.nhs.uk/articles/prescribing-by-generic-or-brand-name/). That demonstrates system-level benefits for safety and cost control.

If you’re asking why clinicians need to know Adderall generic name, consider prescribing volume and verification burdens. In the U.S., mixed-amphetamine salts have represented a large share of stimulant prescriptions in recent years ([source](https://www.deadiversion.usdoj.gov/pubs/docs/IQVIA-Report-on-Stimulant-Trends-2024.pdf)), so clear naming is commonly required. At the bedside, a short, citable definition prevents unnecessary tab-hopping and speeds verification. Rounds AI provides concise, evidence-linked definitions with source citations to help clinicians confirm drug identity and labeling. Learn more about Rounds AI's approach to medication verification and evidence-linked clinical answers for teams evaluating safer prescribing workflows.

## Adderall Generic Name: Amphetamine Mixed Salts – Official Definition

The FDA‑recognized nonproprietary name for Adderall® is dextroamphetamine‑amphetamine (often written as amphetamine/dextroamphetamine), as stated in the product label ([FDA Adderall XR Label (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021303s038lbl.pdf)). The product consists of a fixed mixture of four specific amphetamine salts and is commonly described on labels as the mixed salts of a single‑entity amphetamine rather than a single molecular entity ([DailyMed — Amphetamine/Dextroamphetamine (2023)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f22635fe-821d-4cde-aa12-419f8b53db81)). For clinicians querying *adderall generic name definition and official terminology*, Rounds AI maps both the United States Adopted Name (USAN) and the four‑salt composition, providing clickable FDA and DailyMed citations for quick verification. The label also lists the product’s National Drug Code entries and example packaging identifiers; clinicians should consult the [FDA NDC Directory](https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory) and DailyMed for authoritative NDC lookup. The FDA label further notes that the product is a Schedule II controlled substance.

Adderall (dextroamphetamine‑amphetamine) is listed as a Schedule II controlled substance on the FDA label, reflecting U.S. controlled‑substance law and prescribing constraints ([FDA Adderall XR Label (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021303s038lbl.pdf)). Schedule II status carries practical implications for prescribing, dispensing, and documentation; clinicians and pharmacists should confirm the label name and listed active salts when reconciling medications. Labeling conventions require active ingredients, dosage forms, and NDCs to be shown on packaging and in prescribing information; clinicians should rely on the FDA NDC Directory and DailyMed rather than non‑authoritative aggregators. National dispensing data have shown recent increases in stimulant dispensing volumes, which may inform formulary and monitoring decisions ([DEA ARCOS Annual Report 2023](https://www.deadiversion.usdoj.gov/arcos/2023/annual_report.pdf)). Clinicians using Rounds AI can quickly verify label names and citation sources when checking prescriptions—Rounds AI links directly to FDA and compendia sources, reducing reliance on third‑party aggregators. Learn more about Rounds AI's approach to evidence‑linked clinical reference for medication verification and safety.

## Active Ingredients and Salt Composition in the Adderall Generic

Generic Adderall (amphetamine/dextroamphetamine) is a four‑salt mixture: dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine sulfate, and amphetamine aspartate monohydrate ([DailyMed drug information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f22635fe-821d-4cde-aa12-419f8b53db81)). The four salts are present in equal proportions of total amphetamine salts, yielding ~75% dextroamphetamine base and ~25% levoamphetamine base. Rounds AI displays the salt composition and base‑equivalent context with clickable citations to the [FDA Adderall XR label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021303s038lbl.pdf) so you can verify conversion logic at the point of care. Put another way, a total amphetamine base of 10 mg corresponds approximately to 7.5 mg dextroamphetamine base and 2.5 mg levoamphetamine base. Clinicians should interpret labeled milligram strengths as the total amphetamine salt content and translate that to base equivalents when comparing formulations. For precise conversion and product‑specific details, consult the approved label and compendia cited above.

Differences between immediate‑release (IR) and extended‑release (XR) products are driven primarily by formulation release mechanisms rather than the dextro:levo isomer ratio. While salts can have differing physicochemical properties that may be discussed in pharmacology sources, practical differences in onset and duration depend on the product’s release design and observed pharmacokinetics; these details should be confirmed in the approved label and authoritative references. Understanding the 75:25 dextro:levo split helps reconcile potency differences between IR and XR products when converting or substituting. When questions arise about which amphetamine salts are in a generic product or how brands compare, use labeling and trusted references such as institutional pharmacology commentaries ([University of Michigan pharmacology commentary](https://pharmacy.umich.edu/amphetamines-generic-definition)) to guide equivalence. You can also use Rounds AI to quickly access composition details and linked sources for point‑of‑care verification.

## Verifying the Generic Formulation Using FDA Labeling and Rounds AI

#

1. Open the FDA’s Drugs@FDA / NDC Directory and search "amphetamine mixed salts".
2. Locate the product entry matching the prescribed strength and formulation (IR/XR); note the listed active salts.
3. Record the NDC and compare it to the prescription label or pharmacy dispensed product.
4. If needed, consult DailyMed or the SPL (Structured Product Labeling) link on the FDA entry to read the full active-ingredient listing and salt ratios.

For authoritative NDC and label lookups use the FDA NDC Directory ([FDA National Drug Code Directory](https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory)), and confirm full labeling text on DailyMed ([DailyMed — Amphetamine/Dextroamphetamine](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f22635fe-821d-4cde-aa12-419f8b53db81)). When checking extended‑release formulations, cross‑reference the product label such as the Adderall XR label ([FDA Adderall XR Label (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021303s038lbl.pdf)) to verify active salts and formulation details.

#

When you need to verify Adderall’s generic drug FDA labeling quickly, an evidence‑linked assistant speeds the process without sacrificing traceability. Rounds AI returns concise, citation‑first answers that provide citation‑backed answers with clickable links to FDA labels, guidelines, and peer‑reviewed literature, letting you see the active‑salt listing and source at the point of care. Rounds AI accelerates verification by presenting citation‑backed answers in seconds, with direct links to FDA labels and SPL records; try Rounds AI with a 3‑day free trial to evaluate the workflow fit. Use those fast, sourced answers to cross‑check the NDC Directory or DailyMed before acting ([FDA National Drug Code Directory](https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory), [DailyMed — Amphetamine/Dextroamphetamine](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f22635fe-821d-4cde-aa12-419f8b53db81)). Teams using Rounds AI report that citation visibility preserves the evidence chain clinicians need for accountable, bedside verification. Learn more about Rounds AI’s approach to evidence‑linked clinical Q&A and how it can fit your point‑of‑care checks.

In brief: Adderall’s official generic designation is **amphetamine mixed salts** (amphetamine and dextroamphetamine). The formulation combines four salts in a roughly **3:1:1:1** proportion, as described in the FDA prescribing information ([FDA Adderall XR Label (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021303s038lbl.pdf)). It is a Schedule II controlled substance, and the FDA label explicitly lists both the active ingredients and control status you should verify before prescribing or reconciling medications.

A practical, one-minute FDA verification checklist for clinicians and leaders:
- Check the drug name on the label and confirm **“amphetamine mixed salts”** matches the medication order.
- Confirm the listed salts and total milligram strength against the FDA label ([FDA Adderall XR Label (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021303s038lbl.pdf)).
- Note the Schedule II classification and local dispensing or monitoring requirements.
- When switching brand to generic, record the generic descriptor used for billing and formulary reconciliation, aligning with prescribing guidance from the NHS on generic versus brand naming ([NHS Specialist Pharmacy Service – Prescribing by generic or brand name](https://www.sps.nhs.uk/articles/prescribing-by-generic-or-brand-name/)).

For CMOs and clinical leaders, the takeaway is operational and immediate. Standardize the generic terminology in order sets, pharmacy interfaces, and reconciliation templates. Require a quick label check against the FDA prescribing information during medication reconciliation. Doing so lowers cognitive load for prescribers and reduces billing and formulary mismatches tied to brand-versus-generic naming.

There is growing evidence that tools which surface labeling details and linked sources speed verification at the point of care. Use this insight to evaluate knowledge tools that prioritize cited, verifiable answers over unattributed summaries.

Rounds AI delivers evidence‑linked clinical answers that map drug names to authoritative sources, helping teams confirm labels quickly. Teams using Rounds AI can align medication reconciliation and formulary review with guideline and label evidence, reducing ambiguity during handoffs. Rounds AI's approach helps clinical leaders design workflows that require citation‑level verification rather than memory or fragmented searches.

Next steps: update your reconciliation checklist to include the one-minute verification steps above. Share a short guidance note with prescribing teams about using **amphetamine mixed salts** as the preferred generic term. Learn more about Rounds AI’s approach to evidence‑linked clinical answers and how it can support faster, verifiable medication reconciliation and formulary decisions.